MENU
+Compare
KROS
Stock ticker: NASDAQ
AS OF
Oct 15, 11:16 AM (EDT)
Price
$14.06
Change
-$1.03 (-6.83%)
Capitalization
612.89M

KROS Keros Therapeutics Forecast, Technical & Fundamental Analysis

Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs... Show more

KROS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I.Advisor
a Summary for KROS with price predictions
Oct 14, 2025

Aroon Indicator for KROS shows an upward move is likely

KROS's Aroon Indicator triggered a bullish signal on October 06, 2025. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 203 similar instances where the Aroon Indicator showed a similar pattern. In of the 203 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The 50-day moving average for KROS moved above the 200-day moving average on September 25, 2025. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where KROS advanced for three days, in of 292 cases, the price rose further within the following month. The odds of a continued upward trend are .

KROS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 54 cases where KROS's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .

The Momentum Indicator moved below the 0 level on October 10, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on KROS as a result. In of 90 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for KROS turned negative on September 15, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 45 similar instances when the indicator turned negative. In of the 45 cases the stock turned lower in the days that followed. This puts the odds of success at .

KROS moved below its 50-day moving average on October 14, 2025 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where KROS declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. KROS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.867) is normal, around the industry mean (24.376). P/E Ratio (47.156) is within average values for comparable stocks, (54.689). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.175). Dividend Yield (0.000) settles around the average of (0.044) among similar stocks. P/S Ratio (2.597) is also within normal values, averaging (341.418).

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. KROS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

View a ticker or compare two or three
KROS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published Earnings

KROS is expected to report earnings to rise 38.16% to -104 cents per share on October 30

Keros Therapeutics KROS Stock Earnings Reports
Q3'25
Est.
$-1.05
Q2'25
Beat
by $0.37
Q1'25
Beat
by $4.81
Q4'24
Beat
by $0.22
Q3'24
Missed
by $0.13
The last earnings report on August 06 showed earnings per share of -75 cents, beating the estimate of -112 cents. With 2.68M shares outstanding, the current market capitalization sits at 612.89M.
A.I. Advisor
published General Information

General Information

a biopharmaceutical company, which focuses on treatments for rare muscle diseases

Industry Biotechnology

Profile
Fundamentals
Details
Industry
N/A
Address
1050 Waltham Street
Phone
+1 617 314-6297
Employees
136
Web
https://www.kerostx.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
TIMVX18.71N/A
N/A
Nuveen Mid Cap Value R6
SGPIX111.78N/A
N/A
ProFunds Small Cap Growth Inv
FEUIX30.94N/A
N/A
Fidelity Advisor Glbl Capital Apprec I
JBGCX59.68N/A
N/A
JHancock Blue Chip Growth C
CTSIX47.12N/A
N/A
Calamos Timpani Small Cap Growth I

KROS and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, KROS has been loosely correlated with INO. These tickers have moved in lockstep 53% of the time. This A.I.-generated data suggests there is some statistical probability that if KROS jumps, then INO could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To KROS
1D Price
Change %
KROS100%
-5.03%
INO - KROS
53%
Loosely correlated
-1.21%
AXON - KROS
43%
Loosely correlated
-0.75%
RAPT - KROS
39%
Loosely correlated
-5.12%
DNLI - KROS
39%
Loosely correlated
+1.34%
ALT - KROS
39%
Loosely correlated
-1.25%
More